Clinical Trials Directory

Trials / Completed

CompletedNCT00004580

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

Phase I/II Study of ABT-378/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
Sponsor
Abbott · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected patients who previously have taken protease inhibitors. This study also examines how the body handles this combination of anti-HIV drugs.

Conditions

Interventions

TypeNameDescription
DRUGLopinavir/Ritonavir
DRUGNevirapine

Timeline

First posted
2001-08-31
Last updated
2009-02-20

Locations

10 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00004580. Inclusion in this directory is not an endorsement.

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors (NCT00004580) · Clinical Trials Directory